LDN-211904 oxalate is a potent and selective EphB3 inhibitor (IC50 = 0.079 µM); it exhibits good metabolic stability in mouse liver microsomes; it effectively suppresses STAT3 activation, cancer stem cell (CSC) stemness, and cetuximab resistance in colorectal cancer (CRC) when used in combination with cetuximab.